BCL2 and colonic neoplasm: In 2011, Ramos and colleagues [60] observed that epicatechin–gallate exerted anticarcinogenic effects on colon cancer SW480, leading them to apoptosis by caspase-3 activity, imbalance among Bcl-2 anto- and pro-apoptotic protein levels, ERK activation and AKT inhibition at concentrations higher than 20 μM (8.8 μg/mL).